Shopping Cart
- Remove All
Your shopping cart is currently empty
Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan is an effective, non-peptide, and orally active interleukin-1β converting enzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | Inquiry | 3-6 months | |
| 50 mg | Inquiry | 3-6 months | |
| 100 mg | Inquiry | 3-6 months |
| Description | Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan is an effective, non-peptide, and orally active interleukin-1β converting enzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment. |
| Targets&IC50 | IL-1β converting enzyme:1.4 nM (ki) |
| In vivo | Pralnacasan treatment does not appear to affect the weight of the animals. Pralnacasan (0 -50 mg/kg; oral gavage; twice a day; for 6 weeks; female Balb/c mice) treatment decreases joint damage [1]. |
| Synonyms | VX-740, HMR 3480 |
| Molecular Weight | 523.54 |
| Formula | C26H29N5O7 |
| Cas No. | 192755-52-5 |
| Relative Density. | 1.44 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.